Roche touts less onerous schedule for its in-the-eye injection faricimab, hoping to sweeten the sales pitch over Eylea
Regeneron has made its name on the back of wet AMD drug Eylea, but the blockbuster’s dosing schedule of into-the-eye shots every eight weeks is no cakewalk for patients. Roche, looking to take the fight to Eylea with faricimab, thinks it has a lighter schedule that could help sway physicians.
Roughly half of patients across four Phase III trials eligible for extended dosing of faricimab were able to be treated every four months after one year, subsidiary Genentech announced Friday, and nearly 75% could take the experimental drug every three months. Roche has already prepped a hefty data package for its hopeful Eylea competitor, releasing trickling data from four Phase III trials over the last few months in diabetic macular edema and wet AMD.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.